Back to results
US 8,617,886 B2Granted
Compositions and methods for modulating metabolic pathways
AssigneeNuSirt Sciences, Inc.
InventorsMichael Zemel, E. Douglas Grindstaff, II, Antje Bruckbauer
Life of this patent
Estimating the term…
Abstract
Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
Claims30
A composition formulated for oral consumption, comprising:
- (a) at least about 500 mg of leucine and/or at least about 200 mg of one or more leucine metabolites, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and HMB;
- and
- (b) at least about 10 mg of a sirtuin pathway activator;
- wherein the components of (a) and (b) are present in an amount that is effective in increasing sirtuin pathway output by at least about 1 fold as compared to that of component (a) or (b) when being used alone, wherein the increased sirtuin-pathway output is evidenced by an increase in a physiological effect selected from the group consisting of fatty acid oxidation, mitochondrial biogenesis, glucose uptake, palmitate uptake, oxygen consumption, weight loss, visceral adipose tissue loss, insulin sensitivity, an inflammation marker level, vasodilatation, and body temperature, when (i) media from myotubes or adipocytes treated with the composition is administered to the other of the myotubes or adipocytes, (ii) the composition is administered to myotubes or adipocytes, or (iii) the composition is administered to a subject,
- wherein the composition is substantially free of the individual amino acids alanine, glutamic acid, glycine, and proline, and
- wherein the molar ratio of component (a) to (b) in said composition is greater than about 20.
3 more elements
A composition comprising:
- (a) at least about 500 mg of leucine and/or at least about 200 mg of one or more leucine metabolites, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and HMB;
- and
- (b) at least about 10 mg of a sirtuin pathway activator;
- wherein the composition is substantially free of the individual amino acids alanine, glutamic acid, glycine, and proline.
1 more element
A composition comprising:
- (a) at least about 500 mg of leucine and/or at least about 200 mg of one or more leucine metabolites, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and HMB;
- and
- (b) at least about 25 mg of a sub-therapeutic amount of an anti-diabetic agent selected from the group consisting of biguanide and thiazolidinedione;
- wherein the component of (a) and (b) are present in an amount that, when administered to a subject synergistically increases insulin sensitivity in said subject as compared to administering to a subject component (a) or component (b) alone, and
- wherein the composition is substantially free of the individual amino acids alanine, glutamic acid, glycine, and proline.
2 more elements
Dependencies are inferred from the claim text.